Browse the corpus

Levofloxacin is FDA-approved for the treatment of nosocomial pneumonia, community-acquired pneumonia, acute bacterial rhinosinusitis, acute bacterial exacerbation of chronic bronchitis, acute bacterial prostatitis, acute pyelonephritis, urinary tract infection, skin or skin structure infections, prophylaxis, and treatment of plaque due to Yersinia pestis, and to reduce the incidence of disease progression of inhalational anthrax. The drug is in the fluoroquinolone class of medications, and adverse effects include pseudomembranous colitis, hepatotoxicity, and QT prolongation, necessitating patient education on discontinuation if such symptoms arise. This activity reviews monitoring strategies, FDA-issued box warnings, clinical toxicology, and relevant interactions pertinent to healthcare team members in treating patients with bacterial infections. Given this fluoroquinolone's relevance in primary and specialized care, contextualizing the indications of levofloxacin leads to improved clinical practice. Participating clinicians are equipped with the knowledge to seamlessly integrate levofloxacin into the patient-centric framework of clinical practice, ensuring the optimal treatment of bacterial infections. Objectives: Identify the mechanism of action of levofloxacin compared to antibiotics of its class. Differentiate between the FDA-approved and off-label indications of levofloxacin, selecting alternatives when needed. Evaluate the adverse effects, contraindications, and risk factors before prescribing levofloxacin. Implement effective communication among interprofessional team members to improve treatment efficacy for patients who might benefit from levofloxacin. Access free multiple choice questions on this topic.

The elimination half-life of levofloxacin ranges from 27 to 35 hours in adults with renal impairment, depending on severity, compared with 6 to 8 hours in healthy adults. This prolonged half-life indicates that dosing adjustment is necessary for these patients. Neurotoxicity, including non-convulsive status epilepticus, has been reported with levofloxacin.[32] Levofloxacin has a low potential for acute toxicity; however, the stomach needs to be emptied during an acute overdose. The patient should be under observation with adequate maintenance of hydration. Hemodialysis or peritoneal dialysis can not adequately remove levofloxacin. The role of enhancing drug elimination with forced dilution is not clear. Activated oral charcoal administration is also a recommended approach with appropriate conditions.[13]

Levofloxacin is a widely prescribed respiratory fluoroquinolone by many clinicians for a broad spectrum of bacterial infections. Levofloxacin is well-known to increase the risk of tendinitis and tendon rupture in all ages, especially in patients aged over 60, taking corticosteroids, and with a history of kidney, heart, or lung transplants. All prescribers should stratify patients earlier for risk of complications and sparingly use the drug for patients with acute sinusitis, acute bronchitis, and uncomplicated urinary tract infections. Healthcare staff should counsel patients to maintain adequate hydration to prevent crystalluria and avoid antacids to enhance bioavailability. As levofloxacin excretion is primarily via the kidney, clinicians should carefully adjust the dose in the presence of renal insufficiency to prevent levofloxacin accumulation. Consultation with an infectious diseases specialist is required to treat resistant infections. Clinicians should monitor patients for changes in bowel frequency, fever, abdominal cramps, loss of appetite, nausea, vomiting, right upper quadrant tenderness, jaundice, dark-colored urine, or palpitations. Levofloxacin is well-known to cause pseudomembranous colitis, hepatotoxicity, and QT prolongation; patients should receive education to discontinue treatment when the clinical features develop. If diarrhea develops, it is essential to manage fluid and electrolyte replacement in this patient population adequately. Due to the global concern regarding drug resistance of levofloxacin and other fluoroquinolones, limiting the duration of levofloxacin therapy and avoiding its empirical prescribing is important. A cross-sectional study examined changes in fluoroquinolone prescribing patterns following FDA warnings in 2013 and 2016. The research used Medicare data and clinician information from 2011 to 2017, focusing on outpatient visits for specific conditions. The study revealed a general decrease in fluoroquinolone prescriptions, with prescribing behavior influenced by physician and organizational attributes such as hospital affiliation and specialization. This research provides key insights for improving fluoroquinolone de-adoption strategies in response to FDA warnings, which can improve patient safety.[33]

A cross-sectional study examined changes in fluoroquinolone prescribing patterns following FDA warnings in 2013 and 2016. The research used Medicare data and clinician information from 2011 to 2017, focusing on outpatient visits for specific conditions. The study revealed a general decrease in fluoroquinolone prescriptions, with prescribing behavior influenced by physician and organizational attributes such as hospital affiliation and specialization. This research provides key insights for improving fluoroquinolone de-adoption strategies in response to FDA warnings, which can improve patient safety.[33] Clear communication between clinicians (MD, DO, NP,  PA) and nurses is necessary to administer levofloxacin by slow infusion to avoid the risk of hypotension. Pharmacists need to verify dosing and treatment duration and check for drug-drug interactions. Nursing is on the front lines of observing adverse effects and promptly reporting these to the rest of the team. A concerted and collaborative interprofessional team effort between patients, clinicians, nurses, and pharmacists is necessary to achieve improved patient outcomes with reduced risk of adverse drug reactions and increased patient satisfaction related to levofloxacin therapy.